Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial
Key Takeaways
- No GLP-1 medication holds an FDA-approved indication for MASLD or MASH as of May 2026; coverage runs through paired diagnoses
- The ESSENCE phase 3 trial reported positive 2025 results for semaglutide in MASH; an FDA submission is anticipated but the indication has not been granted
- Most fatty liver patients qualify for GLP-1 coverage through type 2 diabetes (Ozempic) or obesity (Wegovy, Zepbound) because MASH overlaps with these populations
- Rezdiffra (resmetirom) became the first FDA-approved MASH drug in March 2024; it is not a GLP-1 and has its own coverage profile (~$47,000/year list)
- If GLP-1 medications receive a MASH indication, expect prior authorization criteria requiring biopsy or non-invasive testing, fibrosis staging, and often a stepped lifestyle trial first
Direct answer
Insurance generally does not cover Ozempic specifically for fatty liver disease as of May 2026 because no GLP-1 medication is FDA-approved for that indication. The semaglutide ESSENCE phase 3 trial reported positive 2025 results and an FDA submission is expected, but no approval has been granted. Practically, fatty liver patients usually access GLP-1 medications through a paired diabetes or obesity diagnosis. If you have MASH plus type 2 diabetes, Ozempic is on-label for the diabetes side. If you have MASH plus obesity (BMI 30+, or 27+ with comorbidity), Wegovy or Zepbound is the more common path.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- The MASLD/MASH naming change and why it matters
- Why no GLP-1 has a fatty liver indication yet
- The ESSENCE trial and what comes next
- Coverage paths that work today
- Rezdiffra: the only approved MASH drug and how it competes
- The diagnostic codes and documentation that influence claims
- Tirzepatide and SYNERGY-NASH
- Out-of-pocket costs and self-pay options
- Medicare, Medicaid, and the indication gap
- Decision framework
- FAQ
- Sources
The MASLD/MASH naming change and why it matters
In June 2023, three major liver societies (AASLD, EASL, ALEH) jointly renamed non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD), and NASH to MASH. The change reflects a positive definition based on metabolic dysfunction, replacing the older "non-alcoholic" framing that defined the disease by what it is not.
The distinction matters because claims documentation, clinical trial enrollment, and FDA labels now use the MASLD/MASH terminology. Older NAFLD/NASH codes still appear in some EHRs and insurance systems; the transition is gradual. Patients sometimes see both used interchangeably.
The MASLD spectrum includes:
- Simple steatosis (MASL). Fat in the liver without significant inflammation. Generally benign in isolation.
- MASH (metabolic dysfunction-associated steatohepatitis). Fat plus inflammation and hepatocyte injury. Progressive risk.
- MASH with fibrosis (F1-F3). Scarring that progresses over time.
- Cirrhosis (F4). Advanced fibrosis with structural liver damage.
FDA approvals for liver-specific drugs target MASH with F2-F3 fibrosis specifically, because that is the population at meaningful risk of progression. Simple steatosis does not require pharmacotherapy in most cases.
Why no GLP-1 has a fatty liver indication yet
GLP-1 medications have been studied in MASLD and MASH for over a decade. Earlier studies (liraglutide LEAN trial 2016; semaglutide phase 2 in NASH 2021) showed improvement in steatosis and biochemical markers. None secured FDA approval because the FDA's MASH endpoint criteria are stringent: improvement in fibrosis without worsening MASH, or MASH resolution without worsening fibrosis, on paired biopsies.
The agency uses biopsy because non-invasive tests (FibroScan, ELF, MRE) have not yet been validated as primary regulatory endpoints, though their use in trials and clinical practice is increasing.
To secure a MASH indication, a drug needs to demonstrate one of the two endpoints on paired biopsy in a randomized trial. The semaglutide ESSENCE trial was designed to meet that bar.
The ESSENCE trial and what comes next
ESSENCE was the phase 3 semaglutide trial in biopsy-confirmed MASH with fibrosis stages F2 or F3. Design summary:
- Population: adults with biopsy-confirmed MASH and fibrosis F2-F3
- Intervention: semaglutide 2.4 mg weekly versus placebo
- Duration: 72 weeks (primary analysis); planned 240-week extension for outcome data
- Primary endpoints (co-primary, FDA-defined for MASH):
- Resolution of MASH without worsening of fibrosis
- Improvement in fibrosis by at least one stage without worsening of MASH
Top-line results reported in 2025 showed semaglutide met both co-primary endpoints with statistical significance. Approximate magnitudes from the published top-line summary: roughly 60-65% of semaglutide patients achieved MASH resolution without fibrosis worsening (versus ~35% placebo), and roughly 35-40% achieved fibrosis improvement (versus ~22% placebo).
The 2025 readout supports a regulatory filing. Novo Nordisk has indicated intent to submit semaglutide for a MASH indication. Typical FDA review timelines suggest a possible approval in 2026 or 2027, though the actual timeline depends on FDA priority and the specifics of the submission.
If approved, semaglutide would become the second FDA-approved MASH drug, after Rezdiffra.
Coverage paths that work today
Until a formal MASH indication exists, fatty liver patients access GLP-1 medications through paired diagnoses. The realistic paths:
Path 1: MASH + type 2 diabetes. The most common pairing. MASH is highly prevalent in type 2 diabetes (estimated 55-70% of T2D patients have MASLD; perhaps 30-40% have MASH). Ozempic is on-label for diabetes. Coverage is typically straightforward.
Path 2: MASH + obesity (BMI 30+). The other common pairing. Wegovy and Zepbound are FDA-approved for obesity. Plans cover them under weight management benefits, subject to prior authorization. The liver benefit accrues as a function of treating the obesity.
Path 3: MASH + obesity-with-comorbidity (BMI 27+). Wegovy and Zepbound at the lower BMI threshold require a comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea). MASH itself is sometimes accepted as the comorbidity, depending on the plan.
Path 4: MASH + established cardiovascular disease. The Wegovy CV indication (2024 FDA expansion based on SELECT trial) opens a coverage path for patients with overweight/obesity and established CVD. MASH patients with established CVD may qualify.
Path 5: MASH alone, without diabetes, obesity, or CVD. The hardest path. Direct insurance coverage of GLP-1 for isolated MASH is essentially unavailable as of May 2026. Patients in this situation typically pursue cash, manufacturer self-pay, or compounded routes.
Rezdiffra: the only approved MASH drug and how it competes
Rezdiffra (resmetirom) became the first FDA-approved MASH drug in March 2024. It is a thyroid hormone receptor beta agonist that reduces hepatic fat and fibrosis through direct effects on liver lipid metabolism, distinct from GLP-1 mechanisms.
| Feature | Rezdiffra (resmetirom) | GLP-1 (semaglutide, anticipated) |
|---|---|---|
| Mechanism | THR-β agonism, direct hepatic effect | GLP-1 receptor agonism; weight loss, metabolic improvement, hepatic effect |
| FDA status | Approved for MASH F2-F3 (March 2024) | Not yet approved for MASH (filing anticipated) |
| Weight effect | Modest weight loss (~3-5% in trials) | Substantial weight loss (~13-17%) |
| Cardiovascular benefit | Lipid improvements; CV outcome data pending | SELECT trial: 20% MACE reduction |
| Diabetes benefit | Modest glycemic effects | Strong glycemic effects (on-label for T2D) |
| Approximate annual cost | ~$47,000 list | ~$11,000-16,000 list (brand) |
| Administration | Oral daily | Subcutaneous weekly |
These drugs occupy different positions in the MASH treatment ecosystem. Rezdiffra is liver-focused; GLP-1 is metabolically broader. For patients whose MASH coexists with obesity, diabetes, or cardiovascular risk, GLP-1 covers multiple problems. For patients whose primary issue is liver-specific without significant comorbidity, Rezdiffra offers a more targeted intervention.
Combination therapy (Rezdiffra plus a GLP-1) is increasingly discussed but not formally studied for safety or additive benefit. Most insurance plans would not cover the combination simultaneously.
The diagnostic codes and documentation that influence claims
The relevant ICD-10 codes for fatty liver claims:
| Code | Diagnosis |
|---|---|
| K76.0 | Fatty (change of) liver, not elsewhere classified (used for MASLD/NAFLD) |
| K75.81 | Nonalcoholic steatohepatitis (NASH/MASH) |
| K74.6x | Other and unspecified cirrhosis of liver |
| E11.x | Type 2 diabetes mellitus |
| E66.x | Obesity codes |
| Z68.x | BMI codes |
| E78.x | Dyslipidemia codes |
Most successful GLP-1 coverage decisions in MASH patients include K75.81 or K76.0 plus an FDA-approved indication code (E11.x for diabetes, E66.x with BMI for obesity).
For Rezdiffra coverage, prior authorization typically requires:
- Biopsy or non-invasive test results documenting MASH and F2-F3 fibrosis
- FibroScan with controlled attenuation parameter and liver stiffness measurement
- ELF score or MRE if biopsy not available
- Hepatology referral or co-management
- Documentation of metabolic comorbidities
When semaglutide is approved for MASH, expect similar prior authorization criteria.
Tirzepatide and SYNERGY-NASH
Eli Lilly's tirzepatide had its own NASH program. The SYNERGY-NASH phase 2 trial reported positive results in 2024: tirzepatide produced MASH resolution rates in the 44-62% range across doses, with corresponding hepatic fat and fibrosis improvements. The phase 3 program is in progress as of May 2026.
If tirzepatide also secures a MASH indication, the market for liver-active GLP-1 medications will have at least two competing products plus Rezdiffra plus various agents in phase 2-3 development (survodutide, efimosfermin, others).
Out-of-pocket costs and self-pay options
Without coverage, approximate cash pricing:
| Medication | List price per month | Self-pay program |
|---|---|---|
| Ozempic | ~$935 | Manufacturer card $25 with commercial insurance |
| Wegovy | ~$1,350 | NovoCare Direct: ~$499 monthly for self-pay vial |
| Mounjaro | ~$1,050 | Savings card eligibility varies |
| Zepbound | ~$1,050 (auto-injector) | Self-Pay Pharmacy: $499-650/month vial |
| Rezdiffra | ~$3,900 | Patient assistance program available |
| Compounded semaglutide | $200-350 | Via telehealth platforms |
| Compounded tirzepatide | $300-450 | Via telehealth platforms |
For patients pursuing weight loss as the path to liver improvement, the compounded route bypasses the indication question entirely. For patients pursuing specific liver-targeted therapy, Rezdiffra (with its higher price but on-label MASH indication) is the only currently approved path.
Medicare, Medicaid, and the indication gap
Medicare Part D. Covers Ozempic for type 2 diabetes. Does not cover Wegovy for obesity alone, though the 2024 SELECT cardiovascular indication created a narrow path for high-CV-risk patients. MASH-specific Medicare coverage of GLP-1 would require both FDA approval and CMS coverage determination, neither of which exists as of May 2026.
Rezdiffra Medicare coverage exists but is uneven. Some Part D plans cover it with prior authorization; others have not added it to formulary.
Medicaid. Coverage varies by state. Most states cover Ozempic for diabetes. MASH-specific coverage is essentially unavailable.
VA and TRICARE. Coverage criteria tightened during the 2023-2024 cost surge. Specific obesity-indication coverage exists with stricter criteria. MASH-only coverage is not currently available.
Decision framework
If you have MASH and type 2 diabetes: Discuss Ozempic, Mounjaro, or Wegovy with your clinician. Coverage is generally available through the diabetes indication. Liver benefits accrue as part of broader metabolic improvement.
If you have MASH and BMI 30+: Wegovy or Zepbound is the most accessible path. Both are FDA-approved for obesity. Liver benefits are well-documented in the surrounding literature even before MASH-specific approval.
If you have MASH with F2-F3 fibrosis and no major comorbidity: Rezdiffra is the only currently FDA-approved option. Coverage exists but with strict prior authorization. Discuss with a hepatologist.
If you have MASH with F2-F3 fibrosis plus obesity or diabetes: Both options (Rezdiffra and a GLP-1) are reasonable. Some clinicians use both, though this is unusual. Most pick one based on the dominant clinical issue.
If you have simple steatosis (MASL, no inflammation, no fibrosis): Lifestyle change is first-line. Pharmacotherapy is rarely indicated. GLP-1 may be appropriate if obesity or diabetes is present.
If you're waiting for semaglutide MASH approval: The submission is anticipated; the timeline depends on FDA review. In the interim, the paths above remain the practical routes.
FAQ
Does insurance cover Ozempic for fatty liver disease? Not directly; no GLP-1 is FDA-approved for MASLD/MASH yet. Coverage runs through type 2 diabetes (Ozempic on-label) or obesity (Wegovy, Zepbound on-label).
What is MASH? Metabolic dysfunction-associated steatohepatitis, formerly NASH. The progressive, inflammatory form of fatty liver disease, with risk of fibrosis and cirrhosis.
What did the ESSENCE trial show? Phase 3 trial of semaglutide 2.4 mg in MASH with F2-F3 fibrosis. Top-line 2025 results showed both co-primary endpoints met: MASH resolution without fibrosis worsening, and fibrosis improvement without MASH worsening. Supports an anticipated FDA filing.
Is Rezdiffra better than GLP-1 for MASH? Different mechanisms. Rezdiffra is more liver-targeted; GLP-1 is broader metabolic. Head-to-head data do not exist. Choice depends on comorbidities.
What is the coverage path now? Pair fatty liver with type 2 diabetes (Ozempic) or obesity (Wegovy, Zepbound). The diabetes path is most reliable; the obesity path requires BMI 30+ or 27+ with comorbidity.
Does Rezdiffra get covered? Yes, with strict prior authorization documenting MASH and F2-F3 fibrosis. List price ~$47,000/year; commercial coverage is increasingly common but still uneven.
Will FDA approval make available GLP-1 coverage for MASH? If approved, yes, with prior authorization criteria similar to Rezdiffra. Plans typically take 6-18 months to update formularies after an approval.
How much does it cost without coverage? Brand-name GLP-1: $935-1,400/month list. Manufacturer self-pay vial programs: $499-650/month. Compounded options through telehealth: $200-450/month.
Does Medicare cover it for MASH? Not currently. Medicare Part D covers Ozempic for diabetes only. No MASH-specific Medicare coverage of GLP-1 exists as of May 2026.
Can I get coverage through a hepatologist referral? The referral can support a prior authorization, particularly for Rezdiffra. For GLP-1, the diagnosis pairing matters more than the referring specialty.
What about tirzepatide for MASH? Phase 2 SYNERGY-NASH showed positive results in 2024. Phase 3 is in progress. A tirzepatide MASH indication is plausible but later than semaglutide.
Should I get a biopsy to qualify? Biopsy is the gold standard but invasive. Non-invasive testing (FibroScan, ELF, MRE) is increasingly accepted by plans. Discuss with your hepatologist whether the workup makes sense for your case.
Sources
- Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Annals of Hepatology. 2023.
- ESSENCE Trial Investigators. Semaglutide for Metabolic Dysfunction-Associated Steatohepatitis (top-line 2025).
- Harrison SA et al. Resmetirom (MGL-3196) for the treatment of nonalcoholic steatohepatitis (MAESTRO-NASH). New England Journal of Medicine. 2024.
- FDA Drug Label. Rezdiffra (resmetirom). 2024.
- FDA Drug Label. Ozempic (semaglutide) Prescribing Information. 2024.
- FDA Drug Label. Wegovy (semaglutide) Prescribing Information. 2024.
- FDA Drug Label. Zepbound (tirzepatide) Prescribing Information. 2024.
- Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis With Liver Fibrosis (SYNERGY-NASH). 2024.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). NEJM. 2023.
- AASLD Practice Guidance: Management of Nonalcoholic Fatty Liver Disease. 2023 update.
- CMS Part D Formulary Guidance. 2026.
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). 2024.
Footer disclaimers
Platform Disclaimer. FormBlends provides educational content and connects patients with independent licensed providers. We do not adjudicate insurance claims, prescribe directly, or guarantee any clinical outcome. Information on coverage is general and varies by plan, state, employer, and policy year.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by state-licensed 503A compounding pharmacies in response to individual prescriptions. They do not undergo the FDA review applied to brand-name drugs and are not interchangeable with them.
Results Disclaimer. Trial results cited here describe group averages and primary endpoints. Individual response varies. Statements about pricing, coverage, and policy reflect best information available as of May 2026 and may change as FDA approvals, CMS determinations, and plan formularies update.
Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Rezdiffra is a registered trademark of Madrigal Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by these companies or any government health program.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →